| Dr Ewell Maydell Hollis Iii, MD | |
|
3551 Roger Brooke Dr, Fort Sam Houston, TX 78234-4504 | |
| (210) 916-5586 | |
| Not Available |
| Full Name | Dr Ewell Maydell Hollis Iii |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
| Location | 3551 Roger Brooke Dr, Fort Sam Houston, Texas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003953555 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 0101230465 (Virginia) | Secondary |
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | 0101230465 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ewell Maydell Hollis Iii, MD Po Box 9086, Camp Lejeune, NC 28547-9086 Ph: (910) 451-0703 | Dr Ewell Maydell Hollis Iii, MD 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234-4504 Ph: (210) 916-5586 |
News Archive
An epidemic of the viral disease nephropathia epidemica (NE) has been linked to increases in the vole population caused by hotter summers, milder winters and increased seedcrop production by broadleaf trees.
Scientists in Cambridge have discovered that a brain protein called syntaxin enables fatty molecules, used widely in health supplements, to work in the brain to make it function properly. Lead Scientist, Dr Bazbek Davletov and his colleague Dr Colin Rickman from the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge, UK report their findings in the journal Chemistry and Biology.
The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, announced that Asahi Kasei Pharma Corporation has received approval for its regulatory application to the Japanese Pharmaceutical and Medical Device Agency (PMDA) for XIAFLEX (collagenase clostridium histolyticum) for the treatment of patients with Dupuytren's contracture in Japan.
› Verified 4 days ago
Raubby Sabalerio, D.O. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 000-000-0000 | |
Jon T O'neal, MD, MPH Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-9272 | |
Dr. James Joseph Sheehan Jr., M.D. Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 3851 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-916-2460 | |
Dr. Laura Ann Pacha, MD Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 3551 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-295-2409 | |
Dr. Forrest W. Oliverson, MD, MPH Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 3851 Roger Brooke Dr, Fort Sam Houston, TX 78234 Phone: 210-295-2409 Fax: 210-295-2456 | |
Dr. William Craig Hewitson, M.D. Preventive Medicine Medicare: Medicare Enrolled Practice Location: 3851 Roger Brooke Dr, Mche-qd/credentials, Fort Sam Houston, TX 78234 Phone: 210-916-2460 | |
Dr. Bryan J. Alsip, M.D., M.P.H. Preventive Medicine Medicare: Not Enrolled in Medicare Practice Location: 3851 Roger Brooke Dr, Mche-qd/ Credentials, Fort Sam Houston, TX 78234 Phone: 210-916-2460 |